May 03, 2016

Lilienfeld, Polovoy and Kessel Weigh in on Delaware Director Compensation Cases

Abonnieren

Sprung Link Text

 
To successfully defend legal challenges against compensation committee decisions, biopharmaceutical companies must make greater efforts to obtain the necessary approvals from stockholders.  Healthcare industry partners Doreen Lilienfeld, Brian Polovoy and Mark Kessel co-authored a letter to the editor on this subject that was published in Nature Biotechnology. According to the authors, biopharmaceutical companies will ignore the Delaware director compensation cases at their own peril.

View full article, Delaware Director Compensation Cases

Autoren und Mitwirkende

Doreen E. Lilienfeld

Partner

Compensation, Governance & ERISA

+1 212 848 7171

+1 212 848 7171

+1 650 838 3804

+1 650 838 3804

New York